Dr. Lal PathLabs (LALPATHLAB) Fundamentals 2026 — P/E 56.2x, Revenue Analysis | SniperIQ
Dr. Lal PathLabs (LALPATHLAB) is a India-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ₹28,370 Crore, trading at ₹1699.65 on the BSE. This SniperIQ fundamentals page covers Dr. Lal PathLabs's valuation (P/E 56.2x, P/B 11.3x), profitability (net margin 18.3%), revenue (₹2,763 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dr. Lal PathLabs's market cap?
Dr. Lal PathLabs (LALPATHLAB) has a market capitalization of approximately ₹28,370 Crore, trading at ₹1699.65 on the BSE. Market cap moves with the live share price.
What is Dr. Lal PathLabs's P/E ratio?
Dr. Lal PathLabs's trailing twelve-month P/E ratio is 56.2x, with a price-to-book (P/B) of 11.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dr. Lal PathLabs?
Dr. Lal PathLabs runs a net profit margin of 18.3%, a gross margin of 53.8%, and an operating margin of 22.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dr. Lal PathLabs generate?
Dr. Lal PathLabs reported revenue of ₹2,763 Crore for fiscal year 2026, with net income of ₹505 Crore and earnings per share (EPS) of 30.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dr. Lal PathLabs pay a dividend?
Dr. Lal PathLabs offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dr. Lal PathLabs financially healthy?
Dr. Lal PathLabs carries a debt-to-equity ratio of 0.08x and a current ratio of 3.48x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dr. Lal PathLabs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dr. Lal PathLabs (LALPATHLAB) the key facts are: market cap ₹28,370 Crore, P/E 56.2x, revenue ₹2,763 Crore, 52-week range 1272-1803.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dr. Lal PathLabs's full fundamentals live
Get Dr. Lal PathLabs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.